Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Cortical lesion load associates with progression of disability in multiple sclerosis.
Long-term follow-up of vanishing tumors in the brain: How should a lesion mimicking primary CNS lymphoma be managed?
Improved ability to work after one year of natalizumab treatment in multiple sclerosis. Analysis of disease-specific and work-related factors that influence the effect of treatment.
Long-term adherence of patients with relapsing-remitting multiple sclerosis to subcutaneous self-injections of interferon β-1a using an electronic device: the RIVER study.
Santhera enters agreement with Columbia University to investigate additional potential of Catena® in MELAS
CLARITY – Safety and Efficacy of Oral Cladribine in Subjects with Relapsing-remitting Multiple Sclerosis (MS)
The unidimensional self-efficacy scale for MS (USE-MS): developing a patient based and patient reported outcome.
Vitamin D and multiple sclerosis: a critical review and recommendations on treatment.
A Network Meta-Analysis of Efficacy and Evaluation of Safety of Subcutaneous Pegylated Interferon Beta-1a versus Other Injectable Therapies for the Treatment of Relapsing-Remitting Multiple Sclerosis.
Amiloride HCI Tablets, USP 5 mg
UPDATE 2-FDA panel supports approval of Sanofi's MS drug Lemtrada
Recurrence of disease activity after repeated Natalizumab withdrawals.
Design and screening of a glial cell-specific, cell penetrating Peptide for therapeutic applications in multiple sclerosis.
Embryonic stem cell lines derived from human blastocysts.
Self-perceived performance and satisfaction with performance of daily activities in persons with multiple sclerosis following interdisciplinary rehabilitation.
Acorda Therapeutics announces positive AMPYRA® (dalfampridine) Phase 2 data in people with post-stroke deficits
Physical Activity Behavior Change in Persons With Neurologic Disorders: Overview and Examples From Parkinson Disease and Multiple Sclerosis.
The effects of massage therapy on multiple sclerosis patients' quality of life and leg function.
Progressive outer retinal necrosis in a multiple sclerosis patient on natalizumab.
Managing fatigue in patients with multiple sclerosis.
Multiple sclerosis and progressive resistance training: a systematic review.
The value of specialty pharmaceuticals - a systematic review.
Bullous pemphigoid in a patient with multiple sclerosis being treated with human immunoglobulin.
High dose naltrexone for dyskinesias induced by levodopa.
Sanofi sees US FDA ruling for MS drug Lemtrada in Q4

Pages